Research Reports | Market Assessment
February 2022

Hepatitis C Virus | Access and Reimbursement | US | 2016

Chronic infection with hepatitis C virus (HCV) is a leading cause of advanced liver disease and hepatocellular carcinoma and a common indication for liver transplantation. The 2013-2015 FDA approvals of Gilead’s Sovaldi (sofosbuvir) and Harvoni (sofosbuvir/ledipasvir), combined with Bristol-Myers Squibb’s Daklinza (daclatasvir) and AbbVie’s Viekira Pak (ombitasvir/paritaprevir/ritonavir + dasabuvir), have ushered in the era of interferon (IFN)-free direct-acting antiviral (DAA) therapy for chronic HCV infection and completely reshaped the HCV therapeutic market. The January 2016 approval of Merck & Co.’s Zepatier (elbasvir/grazoprevir) provided a cost-competitive option for genotype 1,4 patients. The FDA’s recent approval of Gilead’s Epclusa (sofosbuvir/velpatasvir) provides the first FDC approved for all HCV genotypes. Hepatitis C Virus | Access & Reimbursement | U.S. examines the market access factors that influence the success of IFN-free DAA therapies in the U.S. market. The series is based on primary research with U.S. gastroenterologists, hepatologists, and infectious disease specialists, as well as PDs/MDs associated with U.S.-based MCOs. This research explores how payers and physicians interact and how reimbursement decisions influence the prescribing and uptake of specific therapies at the brand level.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports